XELJANZ (tofacitinib) is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education